First report on persistent remission of acromegaly after withdrawal of long-term pegvisomant monotherapy.
Growth Horm IGF Res
; 45: 17-19, 2019 04.
Article
en En
| MEDLINE
| ID: mdl-30772778
ABSTRACT
The GH-receptor antagonist pegvisomant (PEG) reduces peripheral IGF-1 synthesis and is used to treat acromegaly patients resistant or intolerant to somatostatin analogues (SSA). Medical therapy is generally life-long in patients with acromegaly, since disease remission is very uncommon after SSA discontinuation and has never been reported after PEG withdrawal. Here, we report for the first time the cases of two acromegaly patients treated with PEG monotherapy for many years because of resistance to SSA, who persistently maintained normal serum IGF-1 levels after PEG withdrawal. The first patient autonomously discontinued PEG treatment after 8â¯years, while in the second case we stopped the treatment after 11â¯years, because slight hypertransaminasemia occurred. After PEG discontinuation, in both cases IGF-1 values remained persistently normal and GH during OGTT regularly suppressed. To date, both patients are still in remission. Therefore, we suggest that PEG could exert unknown antitumoral effects in pituitary tumor cells and that long-term PEG treatment can induce acromegaly remission in some patients.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Acromegalia
/
Hormona de Crecimiento Humana
/
Privación de Tratamiento
Tipo de estudio:
Prognostic_studies
Límite:
Adult
/
Female
/
Humans
Idioma:
En
Revista:
Growth Horm IGF Res
Asunto de la revista:
ENDOCRINOLOGIA
Año:
2019
Tipo del documento:
Article